Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer

Overview

By retrospectively collecting and arranging real-world data of multi-center HR+/HER2- advanced breast cancer in China combined with CDK4/6 inhibitor and endocrine therapy, we analyzed different HER2 expression levels (HER2 0, 1+, 2+ and FISH-), especially Clinical outcomes of endocrine therapy for metastatic breast cancer with low HER2 expression (HER2 1+, 2+ and FISH-), exploring potential biomarkers of CDK4/6 inhibitors, and understanding the outcome characteristics of HER2 heterogeneity in MBC through multivariate analysis , and guide clinical application.

Full Title of Study: “A Multicenter Clinical Study Evaluating Real-world CDK4/6 Inhibitor Combined With Endocrine Therapy in HR+/HER2- Advanced Breast Cancer”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Basic Science
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 1, 2024

Interventions

  • Drug: (CDK)4/6 inhibitor
    • CDK4/6 inhibitor + AI/fulvestrant therapy,According to clinical guidelines or drug instructions, the treating physician will adjust the drug dose in accordance with the clinical reality and the patient’s personal situation.

Arms, Groups and Cohorts

  • Experimental: HR+/HER2- advanced breast cancer patients receiving CDK4/6 inhibitor combined with endocrine therapy
    • According to clinical guidelines or drug instructions, the treating physician will adjust the drug dose in accordance with the clinical reality and the patient’s personal situation.

Clinical Trial Outcome Measures

Primary Measures

  • Progression-free survival (PFS) From enrollment to progression or death (for any reason) Progression-free survival (PFS)
    • Time Frame: Estimated 24 months
    • From enrollment to progression or death (for any reason)

Secondary Measures

  • Objective response rate (ORR)
    • Time Frame: Estimated 24 months
    • Ratio of CR and PR in all subjects
  • Disease Control Rate (DCR)
    • Time Frame: Estimated 24 months
    • Ratio of CR ,PR and SD in all subjects
  • Overall survival (OS)
    • Time Frame: Estimated 36 months
    • From enrollment to death (for any reason)

Participating in This Clinical Trial

Inclusion Criteria

  • 1) Female patients with advanced breast cancer aged ≥18 years. 2) For breast cancer patients diagnosed as HR-positive and HER2-negative by pathological examination, the expression levels of ER, PR, and HER2 were reported by immunohistochemistry in the primary or metastatic lesions. 1. ER positivity and/or PR positivity is defined as: the proportion of tumor cells with positive staining accounts for ≥ 10% of all tumor cells (confirmed by the investigator of the trial center); 2. HER2 negative is defined as: standard immunohistochemistry (IHC) test is 0/1+; HER2 (2+) needs to be tested by FISH, HER2/CEP17 ratio is less than 2.0 or HER2 gene copy number is less than 4 (by the test center of the test center) Investigator review and confirmation). 3) CDK4/6 inhibitors combined with endocrine therapy can conduct complete efficacy evaluation and follow-up information collection. 4) Postmenopausal or premenopausal/perimenopausal female patients can be enrolled. Postmenopausal status, defined as meeting at least one of the following criteria: prior bilateral ovarian surgery; age ≥60 years; age <60 years, menopause for at least 12 months (not due to chemotherapy, tamoxifen, toremide) fen or ovarian suppression) and follicle-stimulating hormone (FSH) and estrogen levels are in the postmenopausal range. Premenopausal or perimenopausal women may also be enrolled, but must be willing to receive LHRHa during the study period. 5) According to RECIST 1.1 criteria, patients must have: a) measurable lesions; b) unmeasurable osteolytic or mixed (osteolytic + osteoblastic) bone lesions in the absence of measurable lesions. Exclusion Criteria:

  • 1) Early breast cancer patients receive CDK4/6 inhibitor drug therapy. 2) HER2 overexpression or gene amplification, such as immunohistochemical score 3+ or positive fluorescence in situ hybridization. 3) Pregnant or lactating female patients. 4) Patients deemed unsuitable for inclusion by the investigator.

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Tianjin Medical University Cancer Institute and Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Chunfang Hao, PhD, 13602031629, haochf@163.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.